City of Hope established the Center for Biomedicine and Genetics (CBG) to ensure that its technological innovations are efficiently translated from the research lab to the clinical setting in a cost-effective and expeditious manner. The center also allows scientific and clinical investigators the freedom to test and refine the most promising new therapeutics.
CBG is recognized as the nation's premier academic biologic manufacturing facility (the “gold standard” for such facilities, according to the Food and Drug Administration), and has been lauded by The New York Times for its leading role in devising innovative methods of rapid drug development.
CBG was founded with generous support from City of Hope’s
National Office Products Industry (NOPI),
and is licensed by the state and federal government to produce pharmaceutical-grade therapeutic compounds.
CBG provides investigators with the isolation, environmental control and security needed for the manufacture of products for human use. It functions as a centralized facility and shared resource, available for multiple investigators both on and off campus.
CBG is a founding member of the Association of Academic Biologics Manufacturers (AABM), whose mission is to establish a cooperative network of nonprofit, academic-based biologics manufacturers. The association serves as a national resource that brings together clinical investigators with manufacturing capacity and expertise, develops and shares facility operations knowledge among members, provides quality, manufacturing and regulatory training opportunities, and holds annual meetings.
GMP-grade Biologics Production
CBG is designed specifically to accommodate small scale (bench-top) production of GMP-grade biologics, viral and nonviral gene therapeutics and modified patient cell populations to support phase I and II clinical trials at City of Hope. Adherence to cGMP (current Good Manufacturing Practices) is essential in ensuring the quality and integrity of manufactured biologics.
Islet Cell Production
The islet cell production facility at CBG provides isolated islet cells for the islet cell resource centers, which are accelerating the study of islet cell transplantation as a potential cure for type 1 diabetes.
An important component of CBG is our Production Partnership Program, which facilitates the development of innovative biologics created by City of Hope investigators, colleagues and partners to treat patients with cancer, diabetes, viral disease and other life-threatening illnesses, and establishes working relationships with regional biopharmaceutical and academic organizations.
The regulatory expertise and manufacturing skill consistently demonstrated by CBG, coupled with leading-edge bioinformatics and clinical trials groups, makes City of Hope an attractive partner for companies looking to streamline drug development and bring exciting new therapeutic technologies to our patients.